The European Commission has granted a marketing authorisation for a new treatment for HIV, Triumeq, that combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
